KLK3 and prostate carcinoma: SST1 is overexpressed in prostate cancer (Sinisi et al., 1997; Kosari et al., 2008) and mediates antiproliferative effects and inhibition of prostate-specific antigen release induced by the SST1-selective agonist BIM-23926 in prostate cancer cell lines (Pedraza-Arevalo et al., 2017).